Anastomosis Assist Device Market Size, Share & Trends Analysis | Global | 2026-2032

Global Anastomosis Assist Device Market Report to 2032

The global anastomosis assist device market was valued at $97.4 million in 2025. It is expected to grow at a compound annual growth rate (CAGR) of 1.9%, reaching $111.2 million by 2032.

This report covers the global market for anastomosis assist devices (AADs), including devices used for joining two blood vessels, usually to restore continuity after resection or to bypass an unresectable disease process.

The analysis includes unit sales, average selling prices (ASPs), procedure numbers, market size, market shares, growth trends, market forecasts through 2032, and historical data back to 2022.

Market growth is supported by CABG procedural benefits, facilitation of OPCAB and MIDCAB procedures, and increased use of risk-mitigation tools in higher-risk surgical patients. However, surgeon preference for traditional suturing and the added cost of AADs continue to limit broader adoption.

Market Overview

The global anastomosis assist device market includes products used to support the creation of vessel connections during surgical procedures. These devices are most closely associated with coronary artery bypass grafting, where reliable anastomosis is critical to restoring blood flow.

AADs are used to join two blood vessels, either to restore continuity after resection or to bypass an unresectable disease process. In CABG procedures, they can support the creation of stronger and more consistent anastomoses while reducing the time needed for this step.

The use of AADs is increasingly viewed as a way to reduce procedural risk during beating-heart coronary artery bypass grafting, also known as off-pump CABG. By enabling proximal anastomosis without aortic clamping, these devices may lower the risk of embolic events and neurological complications.

As more surgical revascularization patients present with advanced age, extensive aortic calcification, or multiple comorbidities, surgeons are more frequently considering additional risk-mitigation tools. This trend is expected to support continued demand for AADs, even as overall CABG volumes remain constrained.

Market Drivers

CABG Procedural Benefits

AADs provide several procedural benefits during CABG. They can create stronger anastomoses that expand and contract with blood flow, supporting more consistent vessel connection.

Traditional suturing methods may require 10 to 25 minutes to complete an anastomosis. AADs can reduce this time to fewer than two minutes, which can improve surgical workflow and reduce time spent on a critical procedural step.

AADs also produce consistent and reproducible anastomoses that are less dependent on surgical technique and skill set. This can make adoption easier for physicians with limited device-specific training. In proximal anastomosis, AADs can also avoid aortic clamping, reducing complications linked to clamping during CABG.

Facilitation of OPCAB Procedures

AADs can support off-pump coronary artery bypass procedures by helping solve one of the main technical challenges of beating-heart surgery. During OPCAB, surgeons must create anastomoses while the heart is still moving.

This makes the procedure technically demanding and can limit adoption among surgeons. AADs allow rapid anastomosis creation and can reduce the need for aortic clamping, which may improve procedural control and reduce risk.

By supporting more efficient anastomosis during OPCAB, AADs may help slow the deceleration of off-pump procedures. This, in turn, can support demand for AADs over the forecast period.

Facilitation of MIDCAB and TECAB Procedures

Minimally invasive direct coronary artery bypass procedures are another driver of AAD demand. MIDCAB procedures can be performed through port-access keyhole methods or endoscopically through totally endoscopic coronary artery bypass.

One of the key challenges in MIDCAB and TECAB procedures is creating reliable anastomoses through limited access. AADs have been developed for use with robotic systems and minimally invasive approaches to help make successful anastomosis more practical.

As minimally invasive and robotic CABG techniques continue to develop, AADs may play a larger role in supporting these procedures. This can help drive further demand in a market where overall CABG volume growth is limited.

Market Limiters

Surgeon Preference

The primary limiter of the AAD market is surgeon preference for traditional, hand-sewn suturing techniques. Anastomosis is considered one of the most critical steps in CABG surgery.

Many surgeons have used sutures for their entire careers and may be reluctant to adopt AAD technology, even when it offers potential benefits. This is especially true when surgeons are confident in their hand-sewn technique and view it as the standard approach.

As long as traditional suturing remains the standard of care and the preferred method among CABG surgeons, growth in the AAD market will remain limited. Device adoption depends not only on clinical benefit, but also on surgeon trust, training, and willingness to change established practice.

Added Cost

AADs add significant cost to CABG procedures compared with traditional suturing. In cost-conscious hospital environments, this can make adoption difficult.

Hospitals are often looking for ways to reduce procedural spending. If an AAD is viewed as optional rather than necessary, its added cost may be considered difficult to justify.

This is especially important in markets where reimbursement does not clearly support the additional device cost. Even when AADs reduce procedure time or may reduce certain risks, hospitals must still evaluate whether the cost is justified within existing budgets.

Constrained CABG Procedure Base

The AAD market is also limited by the overall CABG procedure environment. CABG volumes remain constrained by the continued growth of less invasive interventional alternatives.

Because AADs are tied closely to surgical revascularization, limited CABG growth restricts the overall procedural base for these devices. Even if AAD adoption rises within selected OPCAB, MIDCAB, or higher-risk patients, total market expansion remains linked to the number of eligible CABG procedures.

This makes the market dependent on both procedure volume and penetration. Without meaningful CABG growth, AAD suppliers must rely on greater adoption within existing surgical cases.

Market Coverage and Data Scope

• Quantitative coverage: Market size, market shares, procedure numbers, market forecasts, market growth rates, units sold, and average selling prices.
• Qualitative coverage: Market drivers and limiters, competitive analysis, recent mergers and acquisitions, company profiles, product portfolios, and leading competitors.
• Time frame: Base year 2025, forecasts to 2032, and historical data back to 2022.
• Market modeling: Revenue is analyzed using unit sales and ASPs, supported by procedure numbers, competitive share analysis, and forecast assumptions.
• Device scope: The report covers anastomosis assist devices used to join blood vessels, including products used in CABG procedures to support proximal anastomosis and reduce reliance on traditional hand-sewn suturing.

Markets Covered and Segmentation

Anastomosis Assist Device Market

The report covers the global anastomosis assist device market as a dedicated cardiac surgery device segment.

Anastomosis assist devices are used to join two blood vessels, usually to restore continuity after resection or to bypass an unresectable disease process. In CABG procedures, these devices help create anastomoses between graft vessels and target vessels.

The market is analyzed by market size, market shares, procedure numbers, market forecasts, market growth rates, units sold, and average selling prices.

The report evaluates AAD demand based on CABG procedure volume, adoption in OPCAB and MIDCAB procedures, surgeon preference, device cost, competitive positioning, and the need for risk reduction in high-risk patients.

This structure helps manufacturers, investors, and strategy teams understand how surgical technique, procedural complexity, physician adoption, and cost constraints are shaping the global AAD market.

Competitive Analysis

Getinge was the leader of the global AAD market in 2025. The company derives its market share from the HEARTSTRING(R) proximal seal systems used for performing proximal anastomosis.

Getinge is expected to maintain its current market share over the coming years. Its position is supported by product familiarity and its role in helping surgeons perform proximal anastomosis without aortic clamping.

Advanced Medical Solutions strengthened its cardiovascular offerings in July 2024 through the acquisition of Peters Surgical, a French company specializing in sutures, clips, surgical adhesives, and anastomosis technologies. Peters Surgical had previously expanded its portfolio by acquiring Vitalitec in 2014, which brought the ENCLOSE(R) II Proximal Anastomosis Assist Device under its umbrella.

The ENCLOSE(R) II device eliminates the need for partial aortic clamping by creating a stable, bloodless surgical field and supports up to three anastomoses per device. Marketed as a cost-effective alternative to Getinge's HEARTSTRING(R), ENCLOSE(R) II now enhances AMS's broader surgical solutions lineup.

B. Braun held a notable share of the global AAD market in 2025. The company offers C-Port(R) Flex A, PAS-Port(R), and C-Port(R), which are manufactured by AesDex LLC and distributed by Aesculap. B. Braun is expected to maintain most of its current share, although smaller companies with a stronger AAD focus may capture some share over the forecast period.

Technology and Practice Trends

Proximal Anastomosis Without Aortic Clamping

Avoiding aortic clamping is one of the most important practice trends supporting AAD use. Aortic clamping can create risks, especially in patients with calcified aortas or other vascular risk factors.

AADs that allow proximal anastomosis without clamping may help reduce embolic events and neurological complications.

Beating-Heart CABG Support

AADs are especially relevant in OPCAB procedures because anastomosis must be performed while the heart continues beating.

By reducing the time and difficulty of creating vessel connections, AADs can support more consistent beating-heart surgical workflows.

Minimally Invasive CABG

MIDCAB and TECAB procedures create demand for tools that can support anastomosis through smaller access points.

AADs designed for minimally invasive or robotic use may help make these procedures more practical and reproducible.

Robotic Surgery Compatibility

Some AADs have been developed to work with robotic surgical approaches. This is important because robotic CABG requires precise vessel connection through limited access.

As robotic cardiac surgery develops, device compatibility with these workflows may become more important.

Risk Mitigation in High-Risk Patients

AADs may be particularly useful in patients with advanced age, extensive aortic calcification, prior stroke risk, or multiple comorbidities.

These patients may benefit most from tools that reduce aortic manipulation and support faster, more reproducible anastomosis.

Cost-Focused Adoption

Cost remains a major factor in AAD adoption. Hospitals must decide whether the benefits of shorter anastomosis time, reduced clamping, and more consistent outcomes justify the added device cost.

Manufacturers that can demonstrate clear procedural and economic value may be better positioned for adoption.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

Why This Report

• How large is the global anastomosis assist device market today, and how much is it expected to grow through 2032?
• How are unit sales, procedure numbers, ASPs, and market values changing over time?
• What role do AADs play in CABG procedures?
• How do AADs reduce the time required to perform anastomosis?
• Why is avoiding aortic clamping important in selected CABG patients?
• How can AADs support OPCAB, MIDCAB, and TECAB procedures?
• What role do robotic and minimally invasive approaches play in future AAD demand?
• Why does surgeon preference for hand-sewn suturing remain a major barrier?
• How does added device cost affect hospital adoption?
• Which companies lead the global AAD market?

The Global Anastomosis Assist Device Market Report from iData Research answers these questions with device-level analysis, procedure-based modeling, ASP data, company share insights, and forecasts through 2032. Use it to evaluate demand, benchmark competitors, understand CABG-related innovation, and support commercial planning in the global anastomosis assist device market.